Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 14

779TiP - Commencement of first-in-human phase I/II TCR-T clinical trial targeting shared tumor-specific hotspot mutations in solid tumors

Date

10 Sep 2022

Session

Poster session 14

Topics

Cell-Based Therapy;  Immunotherapy

Tumour Site

Presenters

Maria Pia Morelli

Citation

Annals of Oncology (2022) 33 (suppl_7): S331-S355. 10.1016/annonc/annonc1058

Authors

M.P. Morelli1, M.V. Negrao2, A. Jazaeri3, B. Johnson1, P. Kebriaei4, D. Deniger5, M. Collinson-Pautz5, N. Demars6, J. Heymach2, S. Kopetz1

Author affiliations

  • 1 Gi Medical Oncology Department, MD Anderson Cancer Center, 77030 - Houston/US
  • 2 Department Of Thoracic/head And Neck Medical Oncology, Division Of Cancer Medicine, MD Anderson Cancer Center, University of Texas, 77030 - Houston/US
  • 3 Gynecologic Oncology And Reproductive Medicine Department, The MD Anderson Cancer Center, 77030 - Houston/US
  • 4 Department Of Stem Cell Transplantation And Cellular Therapy, Division Of Cancer Medicine, MD Anderson Cancer Center, 77030 - Houston/US
  • 5 Research And Development, Alaunos Therapeutics Inc., 77054 - Houston/US
  • 6 Clinical Operations, Alaunos Therapeutics Inc., 77054 - Houston/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 779TiP

Background

Adoptive T-cell therapy is an emerging strategy for solid tumors. Cancer cells frequently harbor driver-mutations in KRAS, TP53, and EGFR genes that can be targeted by T-cell receptors (TCRs). These neoepitopes are presented on the tumor cell surface by human leukocyte antigen (HLA) molecules to TCRs. We have developed, using non-viral Sleeping Beauty transposition, a library of TCRs able to target KRAS, TP53 and EGFR mutations for the treatment of solid tumors.

Trial design

This is a first in human phase 1/2 study of TCR-T cell therapy for patients with non-small cell lung, colorectal, endometrial, pancreatic, ovarian and bile duct cancer. Eligible patients have received and failed standard of care therapy for their tumor and have a mutation and HLA type match for a TCR in the library. After enrollment, patients will undergo leukapheresis, optional bridging therapy during manufacturing and lymphodepletion. The patient’s TCR-T cells will be administered to the patient intravenously following lymphodepletion. The starting dose will be 5 x 109 TCR-T cells (Dose Level 1 (DL1)), in the absence of a Dose Limiting Toxicity (DLT) escalating to 4 x 1010 (DL2) and 1 x 1011 (DL3) TCR-T cells, as safety allows. After completion of DL2, an analysis of TCR-T cell persistence will be performed, and, if deemed necessary, interleukin-2 (IL-2) will be administered after the TCR-T cell infusion. The primary objective of the phase I portion is to define the incidence of DLTs and the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) of TCR-T cells administered without IL-2 (Arm A) or with IL-2 (Arm B). Clinical and radiologic responses will be assessed by RECIST (v1.1) at six and 12 weeks after TCR-T cell infusion and every 12 weeks thereafter for up to two years or until study discontinuation, whichever occurs first. All patients will continue to be monitored in a long-term follow-up protocol for up to 15 years post-TCR-T cell infusion. The study has been initiated and enrollment is ongoing.

Clinical trial identification

NCT05194735, 18 January 2022.

Editorial acknowledgement

Legal entity responsible for the study

Alaunos Therapeutics, Inc.

Funding

Alaunos Therapeutics, Inc.

Disclosure

M.V. Negrao: Financial Interests, Institutional, Funding: Mirati, Novartis, Checkmate, Alaunos Therapeutics, Inc., AstraZeneca, Pfizer, Genentech; Financial Interests, Personal, Advisory Board: Mirati, Merck/MSD, Genentech. A. Jazaeri: Financial Interests, Institutional, Funding: Bristol Myers Squibb, Iovance, AstraZeneca, Aravive, Merck, Eli Lilly, Pfizer; Financial Interests, Personal, Advisory Role: Gerson Lehrman Group, Guidepoint, Macrogenics, Bristol Myers Squibb, Agenus, Alkermes, Nurpobe, Avenge Bio, Blueprint, Green Fire Bio, Immune-Onc, TwoXAR; Financial Interests, Personal, Stocks/Shares: Avenge Bio. B. Johnson: Financial Interests, Personal, Advisory Role: Gritstone Bio, Incyte, Taiho Oncology, Insmed Oncology; Financial Interests, Institutional, Funding: Bristol Myers Squibb, Syntrix, Gateway for Cancer Research. D. Deniger: Financial Interests, Personal, Full or part-time Employment: Alaunos Therapeutics, Inc.; Financial Interests, Personal, Stocks/Shares: Alaunos Therapeutics, Inc.. M. Collinson-Pautz: Financial Interests, Personal, Full or part-time Employment: Alaunos Therapeutics, Inc.; Financial Interests, Personal, Stocks/Shares: Alaunos Therapeutics, Inc.. N. Demars: Financial Interests, Personal, Full or part-time Employment: Alaunos Therapeutics, Inc.; Financial Interests, Personal, Stocks/Shares: Alaunos Therapeutics, Inc., Abb AbbVie vie, Verastem Oncology. J. Heymach: Financial Interests, Personal, Advisory Role: AstraZeneca, EMD Serono, Boehringer-Ingelheim, Catalyst, Genentech, GlaxoSmithKline, Hengrui Therapeutics, Eli Lilly, Spectrum, Sanofi, Takeda, Mirati Therapeutics, Bristol Myers Squibb, BrightPath Biotherapeutics, Jannsen Global Services, Nexus Health Systems, Pneuma Respiratory, Kairos Venture Investments, Roche, Leads Biolabs, RefleXion, Chugai Pharmaceuticals; Financial Interests, Institutional, Funding: AstraZeneca, Bristol Myers Squibb, Spectrum, Takeda; Financial Interests, Institutional, Licensing Fees: Spectrum; Financial Interests, Institutional, Royalties: Spectrum. S. Kopetz: Financial Interests, Personal, Advisory Board: Roche, EMD Serono, Merck, Novartis, Lilly, Boehringer Ingelheim, Boston Biomedical, AstraZeneca, Bayer, Pierre Fabre, Redx Pharma, Ipsen, Daiichi, Natera, HalioDx, Jacobio, Pfizer, Repare Therapeutics, GlaxoSmithKline, Jazz, Xilis, AbbVie, Gilead, Mirati, Flame, Servier, Carina, Bicara, Endeavor BioMedicines, Numab Pharma, Janssen; Financial Interests, Personal, Research: Inivata; Financial Interests, Personal, Stocks/Shares: Lutris, Iylon, Navire, Xilis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.

  • Analytics cookies help us improve our website by collecting and reporting information on its usage.

  • We use marketing cookies to build a profile of you as a user through your actions on our site in order to better understand your interests and provide you with pertinent suggestions.